Monday, September 08, 2014

UpdatesPlus-Spondyloarthropathy - Sept 2014 issue now available

The September issue of UpdatesPlus-Spondyloarthropathy is now available. This intelligence service identifies and analyzes key research and development activity across therapy areas including psoriatic arthritis and axial spondyloarthropathies (non-radiographic axial spondyloarthritis and ankylosing spondylitis).  Coverage spans commercial life cycle management, clinical development and pre-clinical proof of concept

In this month we cover:

  • Approved biologics: Including a considerable amount of long-term data presented at EULAR earlier this summer, for example data for Humira in nr-Ax-SpA (ABILITY 1 study) and peripheral SpA (ABILITY 2 study);  1-2yr data from Cimzia studies (RAPID-PsA and RAPID-Ax-SpA); and 5yr data for Simponi (GO-REVEAL).  We present Q2 sales figures (including PsA splits).  Of special note Simponi has grown 63% YoY, across all indications driven in part by the launch of Simponi Aria (iv) for RA.  Studies have now been announced for PsA and AS.  
  • Otezla:  We report on the early launch performance of Celgene's PDE4 inhibitor in the US.  In particular we discuss reasons for the apparent discrepancy between scripts, impressive market share and sales for the treatment of PsA.  We also discuss the failure of POSTURE to meet its primary endpoint in AS.
  • Biosimilars:  We provide a full and up to date overview of biosimilar development in the immunology space.  Most importantly Celltrion has filed Remsima with the FDA
  • Pipeline development:  We offer a detailed and up to date status of the spondyloarthropathy landscape along with clinical timelines.  Much focus is placed on the IL-17 mAbs in the present issue, as late stage efficacy reads out for PsO, Amgen/AZ report data for Brodalumab from its Phase 2b PsA study, and Lilly close SPIRIT P1 for enrollment
To receive a full executive summary of this 57 slide report please contact

Also available are summaries of our recent issues of UpdatesPlus-Psoriasis and UpdatesPlus-Rheumatoid Arthritis


Post a Comment

<< Home